CELL INTELLIGENCE · 肿瘤细胞治疗研究

CEACAM6 作为机器学习衍生的免疫生物标志物用于预测 HR+/HER2-乳腺癌新辅助化疗反应

CEACAM6 as a machine learning derived immune biomarker for predicting neoadjuvant chemotherapy response in HR+/HER2- breast cancer.

CEACAM6 是 HR+/HER2-乳腺癌中有前景的预测性生物标志物，与化疗耐药和免疫抑制相关。整合免疫特征和通路特征的机器学习模型可能优化个性化 NAC 策略。

HR(+) 乳腺癌对 CDK4/6 抑制剂耐药的免疫学机制

An immunological mechanism of resistance to CDK4/6 inhibitors in HR(+) breast cancer.

CD8(+) T 细胞相关的 KCTD5 促进三阴性乳腺癌患者的恶性进展和不良临床结局

CD8(+) T cell‑related KCTD5 contributes to malignant progression and unfavorable clinical outcome of patients with triple‑negative breast cancer.

γδT 细胞在 TNBC 中的治疗作用

The therapeutic role of γδT cells in TNBC.

γδ T 细胞介导的癌症治疗免疫应答：特别关注乳腺癌

γδ T Cell-Mediated Immune Responses for Cancer Therapy: Special Focus on Breast Cancer.

HER2 阳性乳腺癌的整合分子与免疫表型及其对新辅助治疗的应答：一项 NeoALTTO 探索性分析

Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis.

免疫表型分析有望补充当前 HER2 阳性乳腺癌的预测模型，并助力新疗法的开发。